Editorials Application of recent pharmacological research to the clinical practice of anaesthesia 1
It is regretted that in medicine generally many patients~o n?t benefit as much as they might from the apphc.atlon of recen! pharmacological research. This probably apphes more to anaesthesia than to other specialties. Many consultants base their clinical techniques on those which they used in the senior registrar grade at the end of their training. There may be something to be said for a moderately conservative approach to change but one wonders whether some very useful drugs are not passed over completely because of reluctance of clinicians to experiment with new ideas.
It is now generally appreciated that the clinical effect of a drug depends on the operative concentration at receptor site. Patients mostly behave as 'two-compartment models' and with drug movement between body compartments and drug elimination by metabolism or excretion being first order processes. While most anaesthetists know that the T t of thiopentone is the region of four hours, and for this reason it is not a suitable drug for outpatients, are they equally aware that the pharmacokinetics of lignocaine are affected in cardiac failure or do they still believe that a local anaesthetic (without any reference to dosage) is the safest drug for poor-risk patients? Pharmacokinetics is not as simple a topic as one is led to believe for in clinical practice one has to consider the bolus effect, effect of intermittent administration or infusion, self-induced elimination or selfinhibited elimination and late beta-phase variations. Nevertheless, a proper understanding of the action of a drug can only be achieved when its pharmacokinetics are appreciated.
Muscle relaxants are unique in that the ordinary two-compartment model does not explain how their acti vity curves are related to the concentration in the receptor site, and one must postulate a small biophase microcompartment where the peak concentration at the receptor will correlate with the peak clinical effect. Although pancuronium has the T! ofl 00 minutes compared with 40-60 minutes for fazadinium, they both have a similar duration of clinical action and the 90% effect of both drugs has a similar time curve. It is only with large doses that pancuronium will last longer than fazadinium.
When one realizes that the average hospital I Based on symposium held by Section of Anaesthetics 6June 1980 0141-0768/80/100695-03/$01.00/0 patient is receiving 5 to 8 drugs and if he is anaesthetized this number will increase by as many as another 10,then the subject of drug metabolism and interactions assumes great importance. In general, absorption after oral administration is unpredictable and the factors governing this are complex. Changes in gastric pH may playa part. Gastric emptying is more important and of course this is inhibited by narcotic analgesics. We can even have interactions between drugs used in anaesthesia; for example, diazepam will prolong the T! of ketamine. The enzyme inducers not only include the barbiturates, but possibly smoking. The importance of this extends outside the operating theatre, as a young woman on oral contraceptives may become pregnant if she starts taking an enzyme inducer.
Recently attention has been paid to the toxic metabolites of drugs and of course these can be increased in patients who have induced liver microsomal enzyme activity. We are interested in the toxic metabolites ofmethoxyfturane, halothane and fluroxene and it is possible that the so-called 'halothane hepatitis' is the result of a toxic metabolite which occurs in patients with enzyme induction. There is good reason to believe that halothane itself is not hepatotoxic. Liver enzymes may be induced for as long as four weeks after thiopentone, halothane, nitrous oxide and pancuronium anaesthesia and not just thiopentone as had previously been assumed. One wonders whether this will affect the response to a second anaesthetic within this time. Of course drug interactions can be of value clinically because in anaesthesia we use these all the time to produce the desired effect.
There is a continuing search for analgesic drugs which lack morphine-type dependence liability. It is now realized that this is not a simple matter, as we have two possible types of receptors:~ responsible for the morphine type of dependence, and K-responsible for the keto-cyclazine or pentazocine type of dependence. Buprenorphine is a partial agonist at the~receptors and has an unusual 'bell-shaped' response curve. In contrast, the new analgesic butorphanol, which is being developed in the United States, is a K agonist but a J.1 antagonist, and has a similar pharmacological profile to pentazocine with less physical dependence liability than morphine.
Promising research work on endorphins and enkephalins has not resulted in compounds of any importance. The levo-and met-enkephalins are only weak analgesics although a related peptide, FK 33-824, is a more stable compound and may © 1980 The Royal Society of Medicine have some clinical uses. No enkephalins or endorphins which have as yet been synthesized have had any advantages over morphine in man.
An alternative approach to new analgesics is to look for drugs which will affect arachidonic acid metabolism. Arachidonic acid is derived from the phospholipid fraction of cell membranes and is converted to a number of biologically active compounds including the prostaglandins. The enzyme system responsible is collectively known as prostaglandin synthetase. Aspirin and related analgesic drugs inhibit the first enzyme in this system, cyclo-oxygenase, which converts arachidonic acid to the highly reactive endoperoxide P00 2 • Diflunisal, a long acting analgesic and antiinflammatory agent, reduces P00 2 both by inhibiting cyclo-oxygenase and by enhancing the conversion of P00 2 to POH 2 • As yet we do not fully understand the role of analgesia during general anaesthesia or its importance in altering the stress response. A recent approach has involved the use of very large doses of fentanyl and these do abolish the release of adrenocorticotrophic hormone (ACTH) in response to stimuli. The more widely used changes in heart rate and blood pressure are not a good indication of the stress response. Neither are changes in blood sugar. Using the changes in ACTH as a guide, one finds that the early rise in ACTH which follows the skin incision is little affected by small doses of fentanyl but it soon falls again as the stimulus wears off. In contrast, large doses of fentanyl will completely abolish the increase in ACTH levels. Heart rate varies with the type of anaesthesia, being reduced with halothane and increased with pancuronium and this again minimizes the use of this traditional sign of light anaesthesia.
There has been a wide swing away from parenteral premedication in recent years with everincreasing use of oral diazepam and more recently of lorazepam. Diazepam is generally better absorbed by mouth than following intramuscular injection. Although this does not apply to lorazepam, enough is absorbed to give it a place in premedication as its clinical effectslast up to about six hours. It is therefore a useful drug when one cannot readily determine the exact timing of an operation. This is particularly important in obstetrics and, in contrast to diazepam, lorazepam is well-handled by the newborn infant.
The use of anticholinergic drugs in routine premedication is also diminishing. A new quaternary compound, glycopyrrolate, may be more useful due to its minimal effects on the cardiovascular system. An interesting development in the field of preanaesthetic medication is the use of cimetidine. A loading oral dose of 400 mg by mouth on the night before operation, followed by 200 mg 2-hourly, can generally be relied upon to keep the gastric pH above the dangerous level of 2.5.
It is interesting to note that recent research in general anaesthetics in North America has concentrated on inhalation agents whereas European research has mainly involved intravenous drugs. There are two interesting developments in this latter field, both of which may find a permanent place in clinical practice. The water-soluble midazolam would appear to be a useful substitute for the irritant non-solublediazepam, although it does share the individual variation in response of the established compound. Di-isopropyl phenol is a rapidly-acting non-water-soluble drug which is being investigated under the name orICI 35868.It is reliable in action, produces very little extraneous movement and initial reports suggest that it is shorter acting than equivalent doses of thiopentone, methohexitone or Althesin (alphaxalone and alphadolone acetate).
A hazard of carcinogenicity held up the clinical use of isoflurane (Forane) in the United States. This situation appears to have been cleared and it will soon be available there for clinical use. With halogenated inhalational agents one is worried about the amount of free fluoride which is released, and from this point of view this drug appears to be better than any that we have at the moment. Even halothane, when administered to obese patients, can release measurable amounts of free fluoride although the danger here is not as great as with methoxyflurane or even enflurane. Time alone will tell whether these new compounds carry the same risk of effects from repeated administration as have been attributed to halothane.
Perhaps we are reaching a stage when, rather than abandon halothane even for a second administration, we have begun to understand the patients in whom there is a problem and it should not be given under certain circumstances. These include obesity, enzyme induction and a period ofless than six weeks between administrations. We do not really know the degree to which 'halothane hepatitis' is a specific halothane effect but with a better understanding of metabolic pathways, particularly reductive pathways, we should soon be in a better position to decide which inhalation agent is for which patient.
Of course the problems of repeat anaesthesia are not limited to inhalational agents. The large number of papers which appeared in the early 1970s on reactions to propanidid awakened our interest in this subject. We have even had a few cases reported with thiopentone, but it was only with Althesin that the hazard was fully appreciated. It will be many years before we will be able to judge the circumstances in which a second administration is better avoided and certainly change the drug ifthere has been a reaction to it on the first occasion. It is likely that continuing research will focus on water-soluble compounds, for by removing Cremophor or other organic solvents one is at least removing one of the possible causative factors.
In the field of neuromuscular blocking drugs, current research appears to be concentrated on modifications of the steroid molecule and drugs derived from this have pancuronium-Iike actions. The new Organon compound NC 45 would appear to be relatively free from cardiovascular effects; it is very similar chemically to pancuronium and is fairly rapidly metabolized. However, in contrast to alcuronium, which appears to 'spare' respiration, apnoea with NC 45 will occur while there is 70% of the hand strength still remaining. Developments from Hungary and the USSR have been with a long-acting muscle relaxant known as pipecurium, but not much is known about this drug as yet.
Research workers in anaesthesia will be interested in the recent memorandum from the Department of Health suggesting modifications in the drug regulations in relation to clinical trials, particularly since some feel that the granting of clinical trials certificates constitutes a source of delay in the development of new drugs, although this view is not held unanimously. The Committee on Safety of Medicines has a staff of about 20 doctors and 80 pharmacists looking continuously at new drug submissions and assessing these, in particular with respect to ensuring that they have a reasonable clinical potential, good quality and especially safety. However a doctor can prescribe any drug he or she wishes for a named patient and many clinical trials are carried out by clinicians getting exemption. If one changes the indication for a drug, then one should notify the licensing authority and ask for an exemption from a clinical trial certificate. This exemption willonly be refused on the grounds of safety. On average there are about 300 exemptions granted per year to doctors and dentists wishing to conduct clinical trials on their own responsibility. In fact, there are twice as many exemptions as clinical trials certificates sponsored by pharmaceutical firms. An interesting new suggestion is that the exemption scheme could be applied to the pharmaceutical industry-data would be submitted as a summary and it would not be necessary to submit raw data as at present. However, all research workers must appreciate that their protocols need to be sanctioned by an Ethical Committee. These modifications in regulations should remove frustrations, although time alone will tell whether the fear of losing new drugs because clinical trials were difficult to carry out, was justified.
There are some new, interesting compounds 01<HJ768/80/ I00697-02/$01.00/0 becoming available for clinical research in anaesthesia. Not every anaesthetist can get involved in these, nor is every holder of the FFA sufficiently knowledgeable to look on himself as a useful clinical pharmacologist. However, all anaesthetists should understand the basic principles underlying drug action, the new concepts of drug metabolism and interactions, the importance of analgesia during anaesthesia and problems of repeat anaesthesia. An understanding of these will bring the benefits of recent pharmacological research to the patient.
John W Dundee Professor ofAnaesthetics Queen's University ofBelfast; President, Section ofAnaesthetics

Patient participation groups
It is less than ten years since the first experiments in forming patients' groups within individual practices. The movement has received encouragement from sociologists and from academic general practice, and there are now around two dozen such groups in the country. Earlier this year the final mark of respectability was bestowed with a study day held at the Royal College of General Practitioners chaired by the President of the College (Pritchard 1980). The proponents of patient participation make a number of claims on behalf of this activity, citing advantages for doctors and patients alike. An important role for such groups is in the area of communication -informing patients about aspects of practice policy and relaying patients' ideas and suggestions back to the doctor. The group may be used to sound out feelings about proposed changes in the arrangements of the practice or to help promote a campaign of health education.
These are reasonable developments and all practices would doubtless benefit from improvement in two-way communication. But in keeping with the egalitarianism of the times, some have looked on lay representation as a way of correcting what they regard as an unequal relationship. This is a highly dubious proposition. Effective relationships are based on mutual respect for essential I 1980 The Royal Society of Medicine
